Background {#Sec1}
==========

Fuzi-Lizhong pill (FZLZP) is a popular Traditional Chinese medicine pill that was originally described in the Classic "Taiping Huimin Heji Ju F/ang" of the Song Dynasty (year 1102 by the Western calendar). It is composed of five herbal medicines, including *Aconitum carmichaeli* Debx. (Fuzi), *Codonopsis pilosula* (Franch.) Nannf. (Dangshen), *Atractylodes macrocephala* Koidz. (Baizhu), *Glycyrrhiza uralensis* Fisch. (Gancao) and *Zingiber officinale* Rosc. (Ganjiang). FZLZP is famous for warming the middle-jiao and tonifying the spleen and is used to treat spleen yang deficiency syndrome including enteritis, chronic diarrhoea, irritable bowel syndrome, abdominal pain, vomiting and spasm, peripheral chill, etc. \[[@CR1]--[@CR7]\]. Modern pharmacological research shows that FZLZP possesses a variety of pharmacological activities, including an increase in adaptive thermogenesis, pain relief, anti-inflammation, and spasmolytic benefits \[[@CR8]--[@CR15]\]. Although pharmacological activities of FZLZP have been extensively studied, very little is known about its systematic chemical constituents, and the bioactive compounds that account for its therapeutic effects remain unclear.

In our previous research, we focused on the dissolution behaviour of FZLZP in vitro and the results showed that some constituents in *Aconitum carmichaeli Debx.* and *Glycyrrhiza uralensis* Fisch., such as benzoylaconine, liquiritin and glycyrrhizic acid, were dissolved well in vitro \[[@CR16]--[@CR18]\]. While FZLZP has the so-called active ingredients, there are no empirical data to prove their effectiveness as bioactive compounds. According to the theory of serum pharmacochemistry, while there are multiple components in herbs, only compounds that are absorbed into the blood have the possibility of showing pharmacological bioactivities \[[@CR19]--[@CR24]\]. Therefore, simultaneous identification of systematic chemical constituents in vitro and potential active components in the blood of FZLZP are indispensable.

It was reported that the main components in *Aconitum carmichaeli Debx.* are monoester diterpenoid alkaloids (MDAs) and diester diterpenoid alkaloids (DDAs), which are toxicity and efficacy compounds and should be highly concerned \[[@CR21]\]. Due to the toxicity, Fuzi is usually used in combination with other herbs as a prescription. Some researcher considered the combination to cause the reduction of the absorption of toxic compounds \[[@CR21], [@CR25]\]. As a typical combination, however, there are no detailed studies of this mechanism and the compound variations of FZLZP. The strategy of serum thermochemistry can provide us the accurate qualitative and the preliminary quantitative information for exploring the quantitative change of alkaloids and toxicity reducing mechanism.

Currently, LC--MS is widely applied for the analysis of herbal constituents in vitro and in vivo because of its superior sensitivity, selectivity and ability to conclusively identify the compounds \[[@CR26]--[@CR29]\]. In this study, an approach of high-performance liquid chromatography (HPLC) quadrupole time-of-flight mass spectrometry (QTOF-MS) based on serum pharmacochemistry was developed to identify the phytochemical constituents of FZLZP and multiple absorbed components in rat serum.

Methods {#Sec2}
=======

The Minimum Standards of Reporting Checklist contains details of the experimental design, and statistics, and resources used in this study (Additional file [1](#MOESM1){ref-type="media"}).

Chemicals and materials {#Sec3}
-----------------------

Nine reference compounds were obtained from Sichuan Victor Biological Technology Co. Ltd. (Chengdu China). HPLC grade Ethanol, formic acid and methanol were obtained from Fisher (ThermoFisher Scientific Inc, Waltham, MA, USA). Deionised water (18 MΩ) was prepared by distilled water through a Milli-Q system (Millipore, Milford, MA, USA). Fuzi (No. 1703003), Dangshen (No. 1705003), Baizhu (No. 1704088), Ganjiang (No. 1703060) and Gancao (No. 1703034) were purchased from Sichuan Neautus Traditional Chinese Medicine Co., Ltd. (Chengdu China) and were authenticated by Prof. Jin Pei, Department of Pharmacognosy of Chengdu University of Chinese Medicine.

Preparation of FZLZP {#Sec4}
--------------------

Fuzi, Ganjiang, Dangshen, Baizhu and Gancao were ground into fine powers and weighed according to the instructions recorded in Chinese Pharmacopoeia (2015 edition) and mixed well. Honey was heated at 116--118 °C until bright yellow uniform bubbles appeared on the surface and the honey became sticky. Mixed power and thermal refined honey were mixed at a ratio of 1:0.8 and were made into FZLZP (there is 0.153 kg crude aconite for every 1 kg FZLZP).

Preparation of FZLZP extract samples for LC/MS analysis {#Sec5}
-------------------------------------------------------

FZLZP (1.5 g) was weighed and reflux-extracted with 50 mL 70% ethanol for 1 h. Then, the filtered supernatant sample was rotary evaporated at 40 °C to a concentration of 15 mL, and was centrifuged at 5000 revolutions/min (rpm) for 5 min. The solution was filtered through a 0.22-μm membrane for further analysis.

Animal handling and serum sample preparation {#Sec6}
--------------------------------------------

Eighteen male Sprague--Dawley rats (200 ± 20 g) were obtained from the Sichuan Dashuo Biotechnology Co., Ltd. and were randomly divided into three groups of 6 rats each (group A, FZLZP group for dosed rat serum; group B, Fuzi powder (FZP) group for dosed rat serum; group C, control group for blank rat serum). The animal facilities and protocols conformed to the Care and Use of Laboratory Animals published by the National Institutes of Health. The experiment was approved by the ethical committee of Chengdu University of TCM (No.20161105). The rats were housed in an animal room with a controlled environment (20--25 °C, 65--69% relative humidity, 12 h dark--light cycle), and were given water and fed normal food for 1 week before the experiment. All animals were fasted overnight before the experiments and had free access to water.

The FZLZP was dissolved in 0.5% CMC-Na and were grinded to prepare the FZLZP suspension (150 mg crude drug/mL). Fuzi powder was dissolved in 0.5% CMC-Na to prepare the FZPsuspension (23 mg crude drug/mL, the concentration of FuZi was calculated by the ratio in FZLZP). Group A was intragastric administration 1.5 g/kg body weight of FZLZP suspension for 3 days. Group B was intragastric administration 0.23 g/kg body weight of FZP suspension for 3 days. Group C was intragastric administration with an equivalent volume of 0.5% CMC-Na. Blood samples were collected from the abdominal aorta 45 min after oral administration on the 3rd day and were placed at room temperature for 1 h until solidification. Then, samples were centrifuged at 3000 rpm for 10 min at 4 °C. All samples were stored at − 80 °C until analysis. Three times methanol was added to the 2 mL serum samples, vortexed and then, centrifuged at 12,000 rpm for 20 min. The supernatant was dried with nitrogen gas. The residue was redissolved in 50 μL methanol, vortexed and then, centrifuged at 12,000 rpm for 20 min, and the filtrate was used as the LC/MS sample. 10 µL aliquot was injected for HPLC/MS analysis.

HPLC-QTOF-MS analysis condition {#Sec7}
-------------------------------

Chromatographic analysis was performed in an Agilent 1290 HPLC system controlled with MassHunter Workstation Software (V B.05.00, Agilent Technologies Inc, Santa Clara, CA, USA). Samples were separated on an Agilent HC-C~18~ column (4.6 × 250 mm, 5.0 μm, Agilent Technologies Inc.) held at 35 °C and the flow rate was 1.0 mL/min with the injection volume of 10 μL. The mobile phase consisted of 0.1% formic acid--water (v/v, A) and methanol (B). The optimal gradient elution programme was as follows: 0--15 min, 95--70% A; 15--30 min, 70--48% A; 30--45 min, 48--25% A; 45--48 min, 25--15% A; 48--55 min, 15--2% A; and 55--65 min, 2--2% A.

Mass spectrometry conditions {#Sec8}
----------------------------

Mass spectrometry was performed using an Agilent 6540 QTOF--MS (Agilent Corp., USA) equipped with a Dual AJS electrospray ionization (ESI) source, and the following operating parameters were used: positive mode, drying gas (nitrogen, N~2~); flow rate, 8.0 L/min; gas temperature, 325 °C; nebulizer, 40 psig; sheath gas temperature, 350 °C; sheath gas flow, 11 L/min; capillary voltage, 4000 V; skimmer, 65 V; OCT 1 RF Vpp, 750 V; fragmentor, 110 V. The sample collision energy was set at 10, 20, 30 and 40 V. All the operations, acquisition, and analyses of data were controlled by Agilent LCMS-QTOF Mass Hunter Acquisition Software Ver. B.06.00 (Agilent Technologies Inc.) and operated under Mass Hunter Workstation Software Version B.06.00 (Agilent Technologies Inc.).

Establishment of FZLZP database {#Sec9}
-------------------------------

By searching databases, such as PubMed of the US National Library Medicine and the National Institutes of Health, SciFinder Scholar of American Chemical Society and the Chinese National Knowledge Infrastructure (CNKI) of Tsinghua University, all components reported in the literature on *Aconitum carmichaeli* Debx., *Codonopsis pilosula* (Franch.) Nannf., *Atractylodes macrocephala* Koidz., *Glycyrrhiza uralensis* Fisch. and *Zingiber officinale* Rosc. were summarized in an Agilent PCDL software Ver. B.06.00 (Agilent Technologies Inc.) to establish a database, which includes the name, molecular formula, chemical structure and literatures of each published known compound.

Results {#Sec10}
=======

Characterization of chemical constituents from FZLZP {#Sec11}
----------------------------------------------------

Using the optimal conditions described above, all information on the MS data that was obtained from the robust HPLC-TOF-MS analysis, indicated the retention time and precise molecular mass and provided the MS/MS data. The protonated molecular weights of all target compounds were calculated within an error of 5 ppm. The base peak chromatogram (BPC) of the FZLZP extract sample in positive and negative ion modes are shown in Fig. [1](#Fig1){ref-type="fig"}A, and the data were processed by the Agilent MassHunter Qualitative Analysis B.06.00 Workstation Software with the "find compounds by molecular formula" tool. A total of 73 peaks were obtained, and 67 compounds were identified or tentatively characterized by comparing the *t*~*R*~ values and the MS fragment characteristics of the compounds.Fig. 1The HPLC-ESI/QTOF/MS BPC chromatograms (**A** FZLZP extract samples: **a** in positive mode, **b** in negative mode; **B** Serum samples: **c** controlled serum in positive mode, **d** dosed FZLZP serum in positive mode, **e** dosed FZP serum in positive mode.)

The reference standards are summarized in Table [1](#Tab1){ref-type="table"} and their fragmentation mechanism are proposed in Fig. [2](#Fig2){ref-type="fig"}. The compounds in FZLZP which are identified by the reference standards are summarized and marked in Table [2](#Tab2){ref-type="table"}. For example, reference standards (RS) 1 liquiritigenin in Table [1](#Tab1){ref-type="table"} were detected in the positive ion mode at the Rt in 24.843 min with the *m/z* of 257.0809 (C~15~H~13~O~4~). Its MS/MS data were shown as *m/z* of 239.0698\[M + H--H~2~O\]^+^, 137.0234 \[C~7~H~4~O~3~ + H\]^+^, 121.0293\[C~8~H~8~O + H\]^+^ and 120.0721 \[C~7~H~4~O~3~ + H--OH\]^+^. And the compound 29 in Table [2](#Tab2){ref-type="table"} were detected in the positive ion mode at the Rt in 24.785 min with the *m/z* of 257.0819 (C~15~H~13~O~4~), 239.0707\[M + H--H~2~O\]^+^ and 137.0235 \[C~7~H~4~O~3~ + H\]^+^. Then compound 29 were characterized as liquiritigenin. Similar to the identification process above, among 67 compounds, 9 compounds were identified as benzoylaconine, benzoylmesaconine, benzoylhypaconine, mesaconitine, liquiritigenin, isoliquiritigenin, glycyrrhizic acid, glycyrrhetinic acid and atractylenolide II. The MS data of the (+) ESI--MS spectra are shown in Table [2](#Tab2){ref-type="table"}.Table 1Retention time, m/z values of ions of reference standardsPeak no.Rt (min)Systematic nameMolecular formula\[M + H\]^+^\[M + Na\]^+^Fragmentations (m/z)Measured mass (m/z)Error (ppm)Measured mass (m/z)Error (ppm)124.843LiquiritigeninC~15~H~12~O~4~257.08090.3890257.0809\[M + H\]^+^, 239.0698\[M + H--H~2~O\]^+^, 137.0234 \[C~7~H~4~O~3~ + H\]^+^, 121.0293 \[C~8~H~8~O + H\]^+^, 120.0721 \[C~7~H~4~O~3~ + H--OH\]^+^227.507BenzoylmesaconineC~31~H~43~NO~10~590.2952− 1.3553----590.2952\[M + H\]^+^, 572.2832\[M + H--H~2~O\]^+^, 558.2683\[M + H-CH~3~OH\]^+^, 540.2580\[M + H--CH~3~OH--H~2~O\]^+^328.228BenzoylaconineC~32~H~45~NO~10~604.31302.3167----604.3130\[M + H\]^+^, 586.2995\[M + H--H~2~O\]^+^, 572.2852\[M + H--CH~3~OH\]^+^\
554.2735\[M + H--2H~2~O\]^+^, 540.2577\[M + H--CH~3~OH\]^+^, 522.2475\[M + H--2CH~3~OH--H~2~O\]^+^429.152BenzoylhypaconineC~31~H~43~NO~9~574.3003− 1.3930----574.3003\[M + H\] + , 542.2741\[M + H--CH~3~OH\]^+^, 524.2615\[M + H--CH~3~OH--H~2~O\]^+^, 510.2477\[M + H--2CH~3~OH\]^+^531.663MesaconitineC~33~H~45~NO~11~632.3064− 0.1582----632.3064\[M + H\]^+^, 600.2787\[M + H--CH~3~OH\]^+^, 572.2853\[M + H--AcOH\]^+^, 540.2594\[M + H--AcOH--CH~3~OH\]^+^, 512.2637\[M + H--AcOH--CH~3~OH--CO\]^+^,639.648IsoliquiritigeninC~15~H~12~O~4~257.08090.3890257.0809\[M + H\]^+^, 239.0692\[M + H--H~2~O\]^+^, 137.0235\[C~7~H~4~O~3~ + H\]^+^, 121.0287 \[C~8~H~8~O + H\]^+^, 120.0514 \[C~7~H~4~O~3~ + H--OH\]^+^748.854Atractylenolide IIC~15~H~20~O~2~233.15380.8578233.1538\[M + Na\]^+^, 215.1440\[M + Na--H~2~O\]^+^, 187.1484\[M + Na--CH~2~O~2~\]^+^, 159.1165\[M + Na--CH~2~O~2~--C~2~H~4~\]^+^, 145.101 \[M + Na--CH~2~O~2~--C~3~H~6~\]^+^\
131.0856\[M + Na--CH~2~O~2~--C~4~H~8~\]^+^, 105.0702\[M + Na--CH~2~O~2~--C~4~H~8~--C~2~H~2~\]^+^,849.134Glycyrrhizic acidC~42~H~62~O~16~845.39472.0109845.3947\[M + Na\]^+^, 669.3614\[M + Na--(GluA--H~2~O)\]^+^955.125Glycyrrhetinic acidC~30~H~46~O~4~471.3458− 2.3337471.3458\[M + H\]^+^, 453.3349\[M + H--H~2~O\]^+^, 435.3244\[M + H-2H~2~O\]^+^ Fig. 2The mass fragment and fragmentation pathway of **a** Liquiritigenin, **b** Benzoylmesaconine, **c** Benzoylaconine, **d** Benzoylhypaconine, **e** mesaconitine, **f** Isoliquiritigenin, **g** Atractylenolide II, **h** Glycyrrhizic acid, **i** Glycyrrhetinic acid Table 2Identification information of constituents in vitro of FZLZP by HPLC-ESI/QTOF/MSPeak no.Rt (min)Systematic nameMolecular formulaMolecular weight\[M + H\]^+^\[M + Na\]^+^Fragmentations (m/z)SourceMeasured mass (m/z)Error (ppm)Measured mass (m/z)Error (ppm)15.091[l]{.smallcaps}-Pyroglutamic acidC~5~H~7~NO~3~129.0426130.05054.6136130.0505\[M + H\]^+^, 112.0123\[M + H--H~2~O\]^+^, 84.0449\[M + H--HCOOH\]^+^Dangshen28.051CodonopsineC~14~H~21~NO~4~267.1471268.15430268.1543\[M + H\]^+^, 250.1451\[M + H--H~2~O\]^+^,\
205.0863\[M + H--2CH~3~OH\]^+^Dangshen39.2295-hydroxymethyfurfuralC~6~H~6~O~3~126.0317127.03943.1486127.0394\[M + H\]^+^, 109.0291\[M + H--H~2~O\]^+^Dangshen49.398KarakolidineC~22~H~35~NO~5~393.2515394.25900.5072394.2590\[M + H\]^+^, 376.2489\[M + H--H~2~O\]^+^, 358.2371\[M + H--2H~2~O\]^+^Fuzi510.142PhenylalanineC~9~H~11~NO~2~165.0790166.08725.4188166.0872\[M + H\]^+^, 120.0817\[M + H--HCOOH\]^+^Dangshen611.288Senbusine AC~23~H~37~NO~6~423.2621424.26960.4713424.2696\[M + H\]^+^, 406.2579 \[M + H--H~2~O\]^+^Fuzi711.4079-OH-senbusine AC~23~H~37~NO~7~439.2570440.2635− 1.8170440.2635\[M + H\]^+^, 422.2531\[M + H--H~2~O\]^+^, 408.2318\[M + H--CH~3~OH\]^+^Fuzi812.04216-β-hydroxycardiopetalineC~21~H~33~NO~4~363.2410364.2480− 0.5490364.2480\[M + H\]^+^, 346.2372\[M + H--H~2~O\]^+^, 328.2273\[M + H--2H~2~O\]^+^Fuzi912.389MesaconineC~24~H~39~NO~9~485.2625486.2697− 0.2056486.2697 M + H\]^+^, 468.2573\[M + H--H~2~O\]^+^, 436.2323\[M + H--H~2~O--CH~3~OH\]Fuzi1012.578SongorineC~22~H~31~NO~3~357.2304358.23821.3957358.2382\[M + H\]^+^, 340.2267\[M + H--H~2~O\]^+^Fuzi1112.908KarakolineC~22~H~35~NO~4~377.2566378.26390378.2639\[M + H\]^+^, 360.2533\[M + H--H~2~O\]^+^Fuzi1213.081IsotalatizidineC~23~H~37~NO~5~407.2672408.2743− 0.2449408.2743\[M + H\]^+^, 390.2630\[M + H--H~2~O\]^+^, 372.2517\[M + H--2H~2~O\]^+^, 358.2374\[M + H--H~2~O--CH~3~OH\]^+^Fuzi1313.109Senbusine BC~23~H~37~NO~6~423.2621424.27073.0640424.2707\[M + H\]^+^, 406.2584 \[M + H--H~2~O\]^+^Fuzi1413.93714-AcetylkarakolineC~24~H~37~NO~5~419.2672420.27501.4276420.2750\[M + H\]^+^, 402.1695\[M + H--H~2~O\]^+^,\
356.1122\[M + H--H~2~O--2CH~3~OH\]^+^,Fuzi1514.091AconineC~25~H~41~NO~9~499.2781500.2850− 0.7995500.2850\[M + H\]^+^, 482.2741\[M + H--H~2~O\]^+^, 468.2564\[M + H--CH~3~OH\]^+^, 450.2478\[M + H--H~2~O--CH~3~OH\]^+^, 436.2309\[M + H--2CH~3~OH\]^+^, 418.2209\[M + H--H~2~O--2CH~3~OH\]^+^Fuzi1614.380HetisineC~20~H~27~NO~3~329.1991330.20640330.2064\[M + H\]^+^, 312.1951\[M + H--H~2~O\]^+^Fuzi1715.319HypaconineC~24~H~39~NO~8~469.2676470.2744− 0.8506470.2744\[M + H\]^+^, 453.2301\[M + H--OH\]^+^, 438.2474\[M + H--CH~3~OH\]^+^, 406.2212\[M + H--2CH~3~OH\]^+^, 374.1941\[M + H--3CH~3~OH\]^+^Fuzi1815.810FuzitineC~20~H~23~NO~4~341.1627342.1697− 0.8767342.1697\[M + H\]^+^, 324.1026\[M + H--H~2~O\]^+^Fuzi1916.070FuzilineC~24~H~39~NO~7~453.2727454.28000.2201454.2800\[M + H\]^+^, 436.2677\[M + H--H~2~O\]^+^, 418.2583\[M + H--2H~2~O\]^+^, 404.2443\[M + H--H~2~O--CH~3~OH\]^+^, 386.2295\[M + H--2H~2~O--CH~3~OH\]^+^, 354.2069\[M + H--2H~2~O--2CH~3~OH\]^+^Fuzi2016.248Tau-cadinolC~15~H~26~O222.1984245.1852− 9.7884245.1852\[M + H\]^+^, 213.0195\[M + H--CH~3~OH\]^+^, 199.1252\[M + H--CH~3~OH--CH~3~\]^+^, 184.9885\[M + H--CH~3~OH--2CH~3~\]^+^,\
169.0055\[M + H--CH~3~OH--3CH~3~\]^+^,Ganjiang2116.573NeolineC~24~H~39~NO~6~437.2777438.2848− 0.4563438.2848 M + H\]^+^, 420.2756\[M + H--H~2~O\]^+^, 388.2478\[M + H--H~2~O--CH~3~OH\]^+^, 370.2365\[M + H--2H~2~O--CH~3~OH\]^+^, 356.2213\[M + H--H~2~O--2CH~3~OH\]^+^Fuzi2216.743TalatisamineC~24~H~39~NO~5~421.2828422.28990.4736422.2899\[M + H\]^+^, 390.2621\[M + H--CH~3~OH\]^+^, 358.2349\[M + H--2CH~3~OH\]^+^Fuzi2318.651ChasmanineC~25~H~41~NO~6~451.2934452.300802210452.3008\[M + H\]^+^, 420.2737\[M + H--CH~3~OH\]^+^Fuzi2419.739GeranialC~10~H~16~O152.1201153.12750.6530153.1275\[M + H\]^+^, 135.1162\[M + H--H~2~O\]^+^, 125.0940\[M + H--CO\]^+^Ganjiang2520.39014-AcetyltalatizamineC~26~H~41~NO~6~463.2934464.30141.5076464.3014\[M + H\]^+^, 432.2753\[M + H--CH~3~OH\]^+^, 414.2645\[M + H--CH~3~OH--H~2~O\]^+^, 400.2486\[M + H--2CH~3~OH\]^+^, 372.2522\[M + H--CH~3~OH--AcOH\]^+^Fuzi2621.8287-hydroxycoumarinC~9~H~6~O~3~162.0317163.03953.0667163.0395\[M + H\]^+^, 145.0627\[M + H--H~2~O\]^+^Baizhu2723.891SchaftosideC~26~H~28~O~14~564.1479565.1542− 1.7694565.1542\[M + H\]^+^, 547.1434\[M + H--H~2~O\]^+^, 529.1303\[M + H--2H~2~O\]^+^, 511.1220\[M + H--3H~2~O\]^+^Gancao2824.041ScopoletinC~10~H~8~O~4~192.0423193.05002.5900193.0500\[M + H\]^+^, 161.0603\[M + H--CH~3~OH\]^+^Baizhu29^\#^24.785LiquiritigeninC~15~H~12~O~4~256.0736257.08194.2788257.0819\[M + H\]^+^, 239.0707\[M + H--H~2~O\]^+^, 137.0235\[C~7~H~4~O~3~ + H\]^+^, 121.0280\[C~8~H~8~O + H\]^+^, 120.0525 \[C~7~H~4~O~3~ + H--OH\]^+^Gancao30^\#^27.065BenzoylmesaconineC~31~H~43~NO~10~589.2887590.2959− 0.1694----590.2959\[M + H\]^+^, 572.2826\[M + H--H~2~O\]^+^, 558.2663\[M + H--CH~3~OH\]^+^ 540.2573\[M + H--CH~3~OH--H~2~O\]^+^Fuzi3127.325IsoviolanthinC~27~H~30~O~14~578.1636579.1700− 1.3812579.1700\[M + H\]^+^, 561.1588\[M + H--H~2~O\]^+^, 543.1485\[M + H--2H~2~O\]^+^, 525.1382\[M + H--3H~2~O\]^+^Gancao32^\#^27.614BenzoylaconineC~32~H~45~NO~10~603.3043604.3114− 0.3309604.3114\[M + H\]^+^, 587.2801\[M + H--OH\]^+^, 554.2711\[M + H--2CH~3~OH\]^+^Fuzi33^\#^28.595BenzoylhypaconineC~31~H~43~NO~9~573.2938574.30110574.3011\[M + H\]^+^, 542.2745\[M + H--CH~3~OH\]^+^,,510.2457\[M + H--2CH~3~OH\]^+^Fuzi3428.748LobetyolininC~26~H~38~O~13~558.2312581.2203− 0.3441581.2203\[M + Na\]^+^, 419.1709\[M + Na--C~6~H~10~O~5~\]^+^Dangshen3531.019Liquiritin apioside or Isoliquiritin apiosideC~26~H~30~O~13~550.1686551.1751− 1.4514551.1751\[M + H\]^+^, 419.1333\[M + H--(Apiose--H~2~O)\]^+^, 257.0830\[M + H--(Apiose--H~2~O)--(Glc--H~2~O)\]^+^Gancao36^\#^31.163MesaconitineC~33~H~45~NO~11~631.2993632.30670.3163----632.3067\[M + H\]^+^, 614.1110\[M + H--H~2~O\]^+^,\
600.2748\[M + H--CH~3~OH\]^+^, 572.2834\[M + H--AcOH\]^+^Fuzi3731.4237-methoxy-liquiritinC~22~H~22~O~9~430.1264431.1332− 1.1597431.1332\[M + H\]^+^, 269.0811\[M + H--(Glc--H~2~O)\]^+^Gancao3831.64614-BenzoylneolineC~31~H~43~NO~7~541.3040542.31354.2411542.3135\[M + H\]^+^, 524.3010\[M + H--H~2~O\]^+^,\
510.2731\[M + H--CH~3~OH\]^+^, 492.2733\[M + H--H~2~O--CH~3~OH\]^+^Fuzi3931.659Dehydrated benzoylhypaconineC~31~H~41~NO~8~555.2832556.29060.1798556.2906\[M + H\]^+^, 524.2647\[M + H--CH~3~OH\]^+^, 492.2381\[M + H--2CH~3~OH\]^+^Fuzi4031.683Liquiritin or IsoliquiritinC~21~H~22~O~9~418.1264419.13350.4771419.1335\[M + H\]^+^, 257.0811\[M + H--(Glc--H~2~O)\]^+^Gancao4131.921AconifineC~34~H~47~NO~12~661.3098662.31720.1509662.3172\[M + H\]^+^, 644.3095\[M + H--H~2~O\]^+^,\
626.1346 \[M + H--2H~2~O\]^+^Fuzi4232.100HypaconitineC~33~H~45~NO~10~615.3043616.31160616.3116\[M + H\]^+^, 584.2843\[M + H--CH~3~OH\]^+^\
556.2899\[M + H--C~2~H~4~O~2~\]^+^, 524.2533\[M + H--C~2~H~4~O~2~--CH~3~OH\]^+^, 496.2678\[M + H--C~2~H~4~O~2~--CH~3~OH--CO\]^+^Fuzi4332.245FormononetinC~16~H~12~O~4~268.0736269.08142.2298269.0814\[M + H\]^+^, 254.0580\[M + H--CH~3~\]^+^, 237.0536\[M + H--CH~3~OH\]^+^, 225.0554\[M + H--CH~3~--CO\]^+^, 213.0908\[M + H--C~2~O~2~\]^+^, 181.0666\[M + H--C~2~O~2~--CH~3~OH\]^+^Gancao4432.528AconitineC~34~H~47~NO~11~645.3149646.3216− 0.9283646.3216\[M + H\]^+^, 628.3140\[M + H--H~2~O\]^+^,\
596.2849\[M + H--H~2~O--CH~3~OH\]^+^Fuzi4533.241DeoxyaconitineC~34~H~47~NO~10~629.3200630.32730630.3273\[M + H\]^+^, 598.3070\[M + H--CH~3~OH\]^+^Fuzi4636.853EchinatinC~16~H~14~O~4~270.0892271.0963− 0.7377271.0963\[M + H\]^+^, 253.0850\[M + H--H~2~O\]^+^Gancao4738.085Benzoic acidC~7~H~6~O~2~122.0368123.04474.8763123.0447\[M + H\]^+^, 77.0379\[M + H--HCOOH\]^+^Baizhu48^\#^39.763IsoliquiritigeninC~15~H~12~O~4~256.0736257.08142.334257.0814\[M + H\]^+^, 239.0704\[M + H--H~2~O\]^+^, 137.0235\[C~7~H~4~O~3~ + H\]^+^, 121.0277\[C~8~H~8~O + H\]^+^, 120.0527 \[C~7~H~4~O~3~ + H--OH\]^+^Gancao4940.720GlycycoumarinC~21~H~20~O~6~368.1260369.13453.2508369.1345\[M + H\]^+^, 333.2235\[M + H--2H~2~O\]^+^,\
313.1057 \[M + H--C~4~H~8~\]^+^,Gancao5041.5136-gingerdioneC~17~H~24~O~4~292.1675293.1736− 2.7520293.1736\[M + H\]^+^, 275.1650\[M + H--H~2~O\]^+^\
257.1517\[M + H--2H~2~O\]^+^Ganjiang5142.593KumatakeninC~17~H~14~O~6~314.0790315.0859− 1.2694315.0859\[M + H\]^+^, 298.2146\[M + H--OH\]^+^,\
279.0782\[M + H--2H~2~O\]^+^Ganjiang5243.4866-gingerolC~17~H~26~O~4~294.1831317.17374.4140317.1771\[M + Na\]^+^, 299.2546\[M + Na-H~2~O\]^+^Ganjiang5343.507Gingerenone-AC~21~H~24~O~5~356.1624357.17103.6397357.1710\[M + H\]^+^, 339.2718\[M + H--H~2~O\]^+^, 321.2612\[M + H--2H~2~O\]^+^Ganjiang5443.5446-shogaolC~17~H~24~O~3~276.1725277.17951.0823277.1795\[M + H\]^+^, 259.1694\[M + Na--H~2~O\]^+^,Ganjiang5545.779lupiwighteoneC~20~H~18~O~5~338.1154339.12393.5385339.1239\[M + H\]^+^, 321.2818\[M + H--H~2~O\]^+^Gancao5646.339Atractylenolide IIIC~15~H~20~O~3~248.1412245.14850249.1485\[M + H\]^+^, 231.1389\[M + H--H~2~O\]^+^, 175.0751\[M + H--H~2~O--2CO\]^+^, 163.0756\[M + H--H~2~O--C~5~H~8~\]^+^Baizhu5748.364Gancaonin LC~20~H~18~O~6~354.1103355.11893.6607355.1189\[M + H\]^+^, 337.2536\[M + H--H~2~O\]^+^Gancao5848.398Licoricesaponin G2C~42~H~62~O~17~838.3987839.40761.9061839.4076\[M + H\]^+^, 663.3722\[M + H--(GluA--H~2~O)\]^+^, 469.3308\[M + H--2 (GluA--H~2~O)--H~2~O\]^+^Gancao59^\#^48.887Atractylenolide IIC~15~H~20~O~2~232.1463233.15412.1445233.1541\[M + Na\]^+^, 187.1485\[M + Na--CH~2~O~2~\]^+^,\
159.0806\[M + Na--CH~2~O~2~--C~2~H~4~\]^+^, 145.1013 \[M + Na--CH~2~O~2~--C~3~H~6~\]^+^, 131.0857\[M + Na--CH~2~O~2~--C~4~H~8~\]^+^, 105.0703\[M + Na--CH~2~O~2~--C~4~H~8~--C~2~H~2~\]^+^Baizhu60^\#^49.296Glycyrrhizic acidC~42~H~62~O~16~822.4038823.41302.3075823.4130 \[M + H\]^+^, 647.3793\[M + H--(GluA--H~2~O)\]^+^Gancao6149.667FarnesalC~15~H~24~O220.1827221.19073.1647221.1907 M + H\]^+^, 192.9740\[M + H--CO\]^+^Ganjiang62^\#^49.841Glycyrrhetinic acidC~30~H~46~O~4~470.3396471.34884.031471.3488\[M + H\]^+^, 453.3354\[M + H--H~2~O\]^+^, 435.3224\[M + H--2H~2~O\]^+^, 425.3378\[M + H--HCOOH\]^+^Gancao6350.671Licorice saponin B2C~42~H~64~O~15~808.4245831.41511.6838831.4151 \[M + Na\]^+^, 655.3825\[M + Na--(GluA--H~2~O)\]^+^,\
479.3547\[M + Na--2 (GluA--H~2~O)\]^+^Gancao6451.232LicoriconeC~22~H~22~O~6~382.1416383.15023.3929383.1502\[M + H\]^+^, 355.1587\[M + H--C~2~H~4~\]^+^Gancao6551.390Atractylenolide IC~15~H~18~O~2~230.1307231.13831.2979231.1383\[M + H\]^+^, 185.1326\[M + H--HCOOH\]^+^,\
157.1012\[M + H--HCOOH--C~2~H~4~\]^+^, 105.0701 \[M + H--HCOOH--2C~2~H~4~--2C\]^+^Baizhu6652.950NeoglycyrolC~21~H~18~O~6~366.1103367.1165− 0.5447367.1165\[M + H\]^+^, 349.2239\[M + H--H~2~O\]^+^,\
335.2389\[M + H--CH~3~OH\]^+^,\
317.2283\[M + H--2H~2~O--CH~3~OH\]^+^Gancao6754.310Licorice-saponin J2C~42~H~64~O~16~824.4194825.42862.3018825.4286\[M + H\]^+^, 649.3906 \[M + H--(GluA--H~2~O)\]^+^, 455.3537\[M + H-2 (GluA--H~2~O)--H~2~O\]^+^, 437.3435 \[M + H-2 (GluA--H~2~O)--2H~2~O\]^+^Gancao^\#^Indicates compounds identified by comparing with the reference standards

The remaining 58 compounds were tentatively characterized based on their chromatographic and spectrometric data, referring to previous literature \[[@CR25], [@CR30]--[@CR33]\]. For example, MS^2^ spectra of compound 4 (molecular ion at *m/z* \[M + H\]^+^ 394.2590) in Table [2](#Tab2){ref-type="table"} gave characteristic fragment ions of \[M + H--H~2~O\]^+^ at *m/z* 376.2489 and \[M + H--2H~2~O\]^+^ at *m/z* 358.2371. Thus, it corresponded to Karakolidine by comparison with literature data \[[@CR30]\]. Moreover, MS^2^ spectra of compound 12 (molecular ion at *m/z* \[M + H\]^+^ 408.2743) in Table [2](#Tab2){ref-type="table"} gave characteristic fragment ions of \[M + H--H~2~O\]^+^ at *m/z* 390.2630, 372.2517\[M + H--2H~2~O\]^+^ and \[M + H--CH~3~OH\]^+^ at *m/z* 358.2374. Then it was identified as Isotalatizidine. All the MS data of the (+) ESI--MS spectra are shown in Table [2](#Tab2){ref-type="table"}. Besides, all the structures of the compounds identified are shown in Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}. The deriving herb for each compound was also assigned. The majority of constituents are identified as alkaloids, flavonoids, triterpenes, gingerols, phenylpropanoids and volatile oil.Fig. 3Structures of compounds identified in the extract of Fuzi Lizhong Pill Fig. 4Structures of compounds identified in the extract of Fuzi Lizhong Pill

Characterization of the absorbed chemical constituents in rat serum {#Sec12}
-------------------------------------------------------------------

### Identification of the bioactive chemical prototype constituents in rat serum {#Sec13}

As the results of constituents in rat serum show in Table [3](#Tab3){ref-type="table"}, by comparing the *t*~*R*~ values and MS fragment characteristics between compounds in serum and compounds in FZLZP extract, 10 alkaloid components sourced from *Aconitum carmichaeli Debx.* were identified, including benzoylaconine, benzoylmesaconine, benzoylhypaconine, mesaconitine, Hypaconitine, fuziline, neoline, talatisamine, chasmanine, and 14-acetyltalatizamine. These constituents have been reported as parts of the main constituents with significant effects of analgesia, anti-inflammation, thermogenesis and increasing blood oxygen in Fuzi \[[@CR34], [@CR35]\]. The MS data of the (+) ESI--MS spectra are shown in Table [3](#Tab3){ref-type="table"}. For example, MS^2^ spectra of compound 19 in Table [2](#Tab2){ref-type="table"} was detected at the Rt in 16.070 min with the molecular ion at *m/z* 454.2800\[M + H\]^+^ and gave characteristic fragment ions of \[M + H--H~2~O\]^+^ at *m/z* 436.2677. Similarly, MS^2^ spectra of compound 2 in Table [3](#Tab3){ref-type="table"} was detected at the Rt in 16.615 min with the molecular ion at *m/z* 454.2808\[M + H\]^+^ and gave characteristic fragment ions of \[M + H--H~2~O\]^+^ at *m/z* 436.0243. Thus, compound 2 in Table [3](#Tab3){ref-type="table"} was identified as the absorbed prototype of Fuziline in rat serum. The other alkaloid components were identified in a similar way.Table 3Characterization of chemical constituents in vivo and metabolites of FZLZP by HPLC-ESI/QTOF/MSPeak no.Rt (min)Systematic nameMolecular formulaMolecular weight (Da)\[M + H\]^+^\[M + Na\]^+^Fragmentations (m/z)Source/prototypeMeasured value (Da)Error (ppm)Measured value (Da)Error (ppm)14.841[l]{.smallcaps}-Pyroglutamic acidC~5~H~7~NO~3~129.0426130.0498− 0.7689130.0498\[M + H\]^+^, 112.9741\[M + H--H~2~O\]^+^Dangshen216.615FuzilineC~24~H~39~NO~7~453.2727454.28081.981454.2808\[M + H\]^+^, 436.0243\[M + H--H~2~O\]^+^Fuzi317.021TalatisamineC~24~H~39~NO~5~421.2828422.29050.9472422.2905\[M + H\]^+^, 390.2651\[M + H--CH~3~OH\]^+^, 359.3263\[M + H--CH~2~OH--CH~3~OH\]^+^Fuzi4\*24.357Glucuronide conjugation metaboliteC~21~H~20~O~10~432.1056433.11320.6927433.1132\[M + H\]^+^, 257.0843\[M + H--(GluA--H~2~O)\]^+^Liquiritigenin525.811LiquiritigeninC~15~H~12~O~4~256.0736257.08194.2788257.0819 \[M + H\]^+^, 239.0713\[M + H--H~2~O\]^+^, 137.0237\[C~7~H~4~O~3~ + H\]^+^Gancao627.236BenzoylmesaconineC~31~H~43~NO~10~589.2887590.2948− 2.033590.2948\[M + H\]^+^, 558.2657\[M + H--CH~3~OH\]^+^ 540.2537\[M + H--CH~3~OH--H~2~O\]^+^, 508.2218\[M + H-2CH~3~OH--H~2~O\]^+^Fuzi727.520BenzoylaconineC~32~H~45~NO~10~603.3043604.31342.97604.3134\[M + H\]^+^, 540.6158\[M + H-2CH~3~OH\]^+^, 508.8095\[M + H-3CH~3~OH\]^+^Fuzi828.379Liquiritin or IsoliquiritinC~21~H~22~O~9~418.1264441.1144− 2.72441.1144 \[M + Na\]^+^, 424.0979 \[M + Na--OH\]^+^, 350.8191\[M + Na--C~6~H~3~O\]^+^Gancao928.595BenzoylhypaconineC~31~H~43~NO~9~573.2938574.30250----574.3025\[M + H\]^+^, 443.8613\[M + H-3CH~3~OH--H~2~O--HO^−^\]^+^Fuzi1031.405MesaconitineC~33~H~45~NO~11~631.2993632.30792.2141632.3079\[M + H\]^+^, 599.9372\[M + H--CH~3~OH\]^+^, 540.2653\[M + H--AcOH--CH~3~OH\]^+^Fuzi1132.453HypaconitineC~33~H~45~NO~10~615.3043616.3089− 4.381616.3089\[M + H\]^+^, 597.8211 \[M + H--H~2~O\]^+^, 556.2792\[M + H--C~2~H~4~O~2~\]^+^Fuzi12\*33.299Glucuronide conjugation metaboliteC30H47NO13629.3047630.329527.7640630.3295 \[M + H\]^+^, 454.8397\[M + H--(GluA--H~2~O)\]^+^Fuziline13\*33.165Glucuronide conjugation metaboliteC~21~H~20~O~10~432.1056433.11453.6942433.1145\[M + H\]^+^, 257.0829\[M + H--(GluA--H~2~O)\]^+^Isoliquiritigenin1440.710IsoliquiritigeninC~15~H~12~O~4~256.0736257.0807− 0.3889257.0807\[M + H\]^+^, 239.1624\[M + H--H~2~O\]^+^Gancao1542.2756-gingerdioneC~17~H~24~O~4~292.1675293.1734− 4.4342293.1734\[M + H\]^+^, 275.1586\[M + H--H~2~O\]^+^Ganjiang1642.514FormononetinC~16~H~12~O~4~268.0736269.0799− 3.3447269.0799\[M + H\]^+^, 181.0511\[M + H--C~2~O~2~--CH~3~OH\]^+^Gancao1744.58414-AcetyltalatizamineC~26~H~41~NO~6~463.2934464.30151.7230464.3015\[M + H\]^+^, 446.2652\[M + H-- H~2~O\]^+^, 432.6414\[M + H--CH~3~OH\]^+^Fuzi1846.5556-gingerolC~17~H~26~O~4~294.1831295.19050.3388295.1905\[M + H\]^+^, 263.1618\[M + H--CH~3~OH\]^+^, 179.1028\[M + H--C~7~H~15~O\]^+^Ganjiang1946.9806-shogaolC~17~H~24~O~3~276.1725277.1781− 6.1332277.1794\[M + H\]^+^, 260.1816\[M + Na--OH\]^+^, 245.1533\[M + H--CH~3~OH\]^+^Ganjiang2047.690Atractylenolide IIC~15~H~20~O~2~232.1463233.1533− 1.2867233.1533\[M + Na\]^+^, 187.1487\[M + Na--CH~2~O~2~\]^+^,\
159.1179\[M + Na--CH~2~O~2~--C~2~H~4~\]^+^, 145.1005\[M + Na--CH~2~O~2~--C~3~H~6~\]^+^Baizhu2148.102ChasmanineC~25~H~41~NO~6~451.2934474.28413.1627474.2841\[M + H\]^+^, 442.0836\[M + H--CH~3~OH\]^+^Fuzi2249.895Glycyrrhizic acidC~42~H~62~O~16~822.4038823.4094− 2.0646823.4094\[M + H\]^+^, 647.3792\[M + H--(GluA--H~2~O)\]^+^Gancao2350.826Atractylenolide IC~15~H~18~O~2~230.1307231.13820.8653231.1382\[M + H\]^+^, 105.9823\[M + H--HCOOH--2C~2~H~4~--2C\]^+^Baizhu2451.095NeolineC~24~H~39~NO~6~437.2777460.2669− 0.2173460.2669 \[M + Na\]^+^, 442.2666\[M + Na--H~2~O\]^+^Fuzi2554.1447-hydroxycoumarinC~9~H~6~O~3~162.0317163.03963.6801163.0396\[M + H\]^+^, 145.5012\[M + H--H~2~O\]^+^Baizhu2656.004Glycyrrhetinic acidC~30~H~46~O~4~470.3396471.3479− 2.122471.3479\[M + H\]^+^, 453.4285\[M + H--H~2~O\]^+^Gancao\* Indicates metabolites

Six compounds sourced from *Glycyrrhiza uralensis* Fisch. were identified, including 3 flavonoids, namely, liquiritigenin, isoliquiritigenin, and formononetin and 2 triterpenes, namely, glycyrrhetinic acid and glycyrrhizic acid. The MS data of the (+)ESI--MS spectra are shown in Table [3](#Tab3){ref-type="table"}. For example, MS^2^ spectra of compound 48 in Table [2](#Tab2){ref-type="table"} was detected at the Rt in 39.763 min with the molecular ion at *m/z* 257.0814\[M + H\]^+^ and gave characteristic fragment ions of 239.0704\[M + H--H~2~O\]^+^, 137.0235\[C~7~H~4~O~3~ + H\]^+^, 121.0277\[C~8~H~8~O + H\]^+^, 120.0527 \[C~7~H~4~O~3~ + H--OH\]^+^. Similarly, MS^2^ spectra of compound 14 in Table [3](#Tab3){ref-type="table"} was detected at the Rt in 40.710 min with the molecular ion at *m/z* 257.0807\[M + H\]^+^ and gave characteristic fragment ions of \[M + H--H~2~O\]^+^ at *m/z* 239.1624. Thus, compound 14 in Table [3](#Tab3){ref-type="table"} was identified as the absorbed prototype of Isoliquiritigenin in rat serum. Furthermore, liquiritin or isoliquiritin may also have been found, but further comparison with reference compounds is needed to identify these isomers. The flavonoids and triterpenes in *Glycyrrhiza uralensis* Fisch. have been reported as having significant anti-inflammatory, abirritation and immunoregulation effects \[[@CR36]--[@CR38]\].

7-Hydroxycoumarin, atractylenolide I and atractylenolide II have been identified as bioactive chemical constituents sourced form *Atractylodes macrocephala* Koidz. (Baizhu) and were found as the main institutes with the effect of anti-inflammatory, antitumor and gastrointestinal regulation in Baizhu \[[@CR39]--[@CR42]\]. The MS data of the (+) ESI--MS spectra are shown in Table [3](#Tab3){ref-type="table"}. For example, MS^2^ spectra of compound 26 in Table [2](#Tab2){ref-type="table"} was detected with the molecular ion at *m/z* 163.0395 \[M + H\]^+^ and gave characteristic fragment ions of 145.0627\[M + H--H~2~O\]^+^. Similarly, MS^2^ spectra of compound 25 in Table [3](#Tab3){ref-type="table"} was detected with the molecular ion at *m/z* 163.0396\[M + H\]^+^ and gave characteristic fragment ions of \[M + H--H~2~O\]^+^ at *m/z* 145.5012. Thus, compound 25 in Table [3](#Tab3){ref-type="table"} was identified as the absorbed prototype of 7-hydroxycoumarin in rat serum.

6-Gingerdione, 6-gingerol and 6-shogaol sourced from *Zingiber officinale* Rosc (Ganjiang) were identified and were reported as having obvious antioxidant, anti-inflammatory, gastrointestinal protective and antitumor effects \[[@CR43], [@CR44]\]. The MS data of the (+) ESI--MS spectra are shown in Table [3](#Tab3){ref-type="table"}. For example, MS^2^ spectra of compound 50 in Table [2](#Tab2){ref-type="table"} was detected with the molecular ion at *m/z* 293.1736\[M + H\]^+^ and gave characteristic fragment ions of 275.1650\[M + H--H~2~O\]^+^, 257.1517\[M + H--2H~2~O\]^+^. Similarly, MS^2^ spectra of compound 15 in Table [3](#Tab3){ref-type="table"} was detected with the molecular ion at *m/z* 293.1734\[M + H\]^+^ and gave characteristic fragment ions of \[M + H--H~2~O\]^+^ at *m/z* 257.1586. Thus, compound 15 in Table [3](#Tab3){ref-type="table"} was identified as the absorbed prototype of 6-gingerdione in rat serum.

One compound was sourced from *Codonopsis pilosula* (Franch.) Nannf. (Dangshen) and was identified as [l]{.smallcaps}-pyroglutamic acid. MS^2^ spectra of compound 1 in Table [2](#Tab2){ref-type="table"} was detected with the molecular ion at *m/z* 130.0505\[M + H\]^+^ and gave characteristic fragment ions of 112.0123\[M + H--H~2~O\]^+^, 84.0449\[M + H--HCOOH\]^+^. Similarly, MS^2^ spectra of compound 1 in Table [3](#Tab3){ref-type="table"} was detected with the molecular ion at *m/z* 130.0498\[M + H\]^+^ and gave characteristic fragment ions of \[M + H--H~2~O\]^+^ at *m/z* 112.9741. Thus, compound 1 in Table [3](#Tab3){ref-type="table"} was identified as the absorbed prototype of [l]{.smallcaps}-pyroglutamic acid in rat serum.

### Identification of the bioactive metabolites in rat serum {#Sec14}

Based on a comparison of the information for ions, 8 peaks were detected only in dosed serum and were assigned to metabolites. Detailed information about the elemental compositions, retention times, and the characteristic fragment ions of metabolites are shown in Table [3](#Tab3){ref-type="table"}. Alkaloid-, phenylpropanoids- and gingerols-related metabolites are the main metabolic constituents of FZPLP absorbed in vivo, and the main metabolic pathways in vivo were glucuronide conjugation and glucuronide. Identification of the corresponding fragment ions was obvious. For example, compound 4 (24.357 min) in Table [3](#Tab3){ref-type="table"} produced \[M + H\] + at *m/z* 433 and MS^2^ yielded a major ion at *m/z* 257 (− 176, Da with the loss of C~6~H~8~O~6~) in the positive ion mode, combined with the retention time of the reference standard 1 in Table [1](#Tab1){ref-type="table"} and compound 29 in Table [2](#Tab2){ref-type="table"}. Therefore, the peak was identified tentatively as a glucuronide conjugation metabolite of liquiritigenin. Similarly, compound 13 (the *t*~*R*~ 33.165 min) in Table [3](#Tab3){ref-type="table"} has the similar retention time compared with the reference standard 6 in Table [1](#Tab1){ref-type="table"} and compound 48 in Table [2](#Tab2){ref-type="table"}. And it produced \[M + H\] + at *m/z* 433 and MS^2^ yielded a major ion at *m/z* 257 (− 176, Da with the loss of C~6~H~8~O~6~) in the positive ion mode. Therefore, the peak was identified tentatively as a glucuronide conjugation metabolite of isoliquiritigenin. The possible structures of metabolites were elucidated as described above. All of the structures of metabolites were identified, and the MS data of the (+) ESI--MS spectra are shown in Table [3](#Tab3){ref-type="table"}. This article reports these metabolites of FZLZP for the first time. The bioactivities are the subject of ongoing research.

Alkaloids difference between Group A and Group B {#Sec15}
------------------------------------------------

As the result shows in Fig. [5](#Fig5){ref-type="fig"}a, 10 kinds of alkaloids were detected in Group A. Most of them were trace amounts in vivo, which indicated the alkaloids' poor absorption in the prescription. Conversely, unlike Group A, the amount of the alkaloids in vivo increased obviously in Group B (Fig. [5](#Fig5){ref-type="fig"}b). The difference indicated that the absorption amount of alkaloids in the prescription can be decreased compared to the absorption amount of alkaloids in the herb powder.Fig. 5The difference in the absorbed compounds in vitro and in vivo. (**a** The difference in the absorbed compounds in vitro and in vivo of Group A; **b** The difference in the absorbed alkaloids in vitro and in vivo of Group B.) (Columns: A, [l]{.smallcaps}-pyroglutamic acid; B, Fuziline; C, Talatisamine; D, Benzoylmesaconine; E, Benzoylaconine; F, Benzoylhypaconine; G, Mesaconitine; H, Hypaconitine; I, 14-Acetyltalatizamine; J, Chasmanine; K, Neoline; L, Liquiritigenin; M, Liquiritin or Isoliquiritin; N, Isoliquiritigenin; O, Formononetin; P, Glycyrrhizic acid; Q, Glycyrrhetinic acid; R, 6-gingerdione; S, 6-gingerol; T, 6-shogaol; U, Atractylenolide II; V, Atractylenolide I; W, 7-hydroxycoumarin)

Discussion {#Sec16}
==========

To obtain LC chromatograms of lower pressure, greater baseline stability, better resolution and higher ionization efficiency, methanol and acetonitrile and series of concentrations of aqueous formic acid solution were prepared for analysis. The best result was achieved when the mobile phase consisted of 0.1% formic acid aqueous solution and methanol. Both positive and negative modes were investigated, and the results showed that the positive ion mode was more sensitive and could provide more information for both extract samples and serum samples analyses.

FZLZP is a formula composed under the guidance of traditional Chinese medicine theory. According to TCM theory, *Aconitum carmichaeli Debx.* is the "monarch drug" and the main herb in FZLZP recipe to warm middle jiao and eliminate cold. This was confirmed in this research with 10 constituents among 23 prototype components sourced from *Aconitum carmichaeli* Debx., which maintains the maximum bioactive compounds. *Glycyrrhiza uralensis* Fisch. is frequently prescribed in combination with other herbs to decrease toxicity and to increase efficacy. In this recipe, it is the "envoy drug" and is considered to be the paramount assistant herb, which can detoxify the toxicity of aconitum. In this study, we found that *Glycyrrhiza uralensis* Fisch. was the second most-absorbed herb. The results that some compounds absorbed well in vivo derived from *Aconitum carmichaeli Debx.* and *Glycyrrhiza uralensis* Fisch. are consistent with our previous studies that they were dissolved very well in vitro \[[@CR16]\].

Alkaloids in Fuzi herb are the toxicity as well as the efficacy compounds. The prescriptions which contains Fuzi herb should be highly concerned. In our study, the results on the differences in alkaloids between Group A and Group B show that the amount of absorption of bioactive constituents in Fuzi can be significantly reduced when this herb is used as part of a prescription rather than used alone. We think there are two reasons. Firstly, according to the TCM theory, the toxicity of Fuzi can be reduced in combination with Gancao \[[@CR25]\]. This should be further confirmed by researching the relationship and differences in the chemistry constituents between Fuzi-Gancao herb pairs in FZLZP. Secondly, the pill form is the embryonic form of sustained-release preparations. As a TCM classic says: only pill among all dosage forms can reduce the toxicity of toxic drugs. The toxic herb was usually made into a pill form to reduce the toxicity in TCM \[[@CR17]\]. And it can be further confirmed by researching differences in the chemistry constituents between FZLZP and the Fuzi pill that made from*Aconitum carmichaeli Debx*. powder.

Conclusions {#Sec17}
===========

This study describes a simple, sensitive and selective HPLC-QTOF-MS method for structural characterization of chemical constituents in FZLZP and bioactive components in rat serum following oral administration of FZLZP. As a result, in vitro, a total of 67 compounds were successfully identified, and 23 prototype compounds that were absorbed in vivo were identified for the first time. In addition, 3 metabolites of the bioactive compounds were tentatively identified. In this prescription, the majority of compounds absorbed in vivo derived from Fuzi and Gancao. The results provide helpful chemical information for FZLZP for further pharmacological and active mechanism research. In addition, it helped to classify the material basis responsible for the therapeutic effects of FZLZP. Furthermore, the HPLC-QTOF-MS was a potentially powerful strategy for simultaneously achieving screening and analysis of multiple bioactive compounds in FZLZP.

Additional file
===============

 {#Sec18}

**Additional file 1.** Minimum standards of reporting checklist.

HPLC-QTOF-MS

:   high-performance liquid chromatography--electrospray ionization/quadrupole-time-of-flight high-definition mass spectrometry

FZLZP

:   Fuzi Lizhong Pill

FZP

:   Fuzi powder

Group A

:   FZLZP group for dosed rat serum

Group B

:   Fuzi powder group for dosed rat serum

Group C

:   control group for blank rat serum
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